Navigation Links
HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
Date:12/17/2008

SAN JOSE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") announced that it has filed a Comprehensive Patent Application with the U.S. Patent and Trademark Office for the use of an innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction.

"We are very excited about the potential of this naturally-occurring compound that we have labeled ER 303. Just inhaling very small quantities resulted in enhanced feelings of confidence, relaxation, affection, warmth, satisfaction and sensuality, in both men and women," a spokesperson indicated. Before the Company perfected the reproduction of this compound, it could only be found in coral reefs off the coasts of Newfoundland and in the waters off Brazil's Guiabinha Island.

"The Patent Application covers use in a wide range of products that may be enhanced and differentiated by the addition of ER 303, including those in the cosmetics and fragrance, personal care, environmental and household fields. Before filing for patent protection, the Company and its scientists have worked for more than eight years from the initial identification, reproducing the compound in the laboratory, conducting psychological and physiological scientific studies with men and women volunteers, and developing a manufacturing process for broad-scale production," the spokesperson also noted. The Company indicated that it is in the process of establishing http://www.ER303.com as its website which will contain additional information about the ER 303 technology and its potential applications for consumer product companies.

The Company has previously been granted broad-based worldwide patents for its initial compound, Androstadienone, which has been licensed to leading marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its affiliates. An HPS spokesperson indicated that the Company believes that this new compound should be of interest to the major consumer products companies around the world.

This news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2007, and Form 10-Q for the nine months ended September 30, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AMERIGROUP Files Shelf Registration Statement
2. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
3. Bally Total Fitness Files for Chapter 11 Bankruptcy Protection
4. Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution
5. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
6. Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign
7. VisiVite.com Files for Patent on Unique Macular Degeneration Supplement
8. State Fund Files an 8.9 Percent Premium Increase for 2009
9. KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
10. Genesis Pharmaceuticals Files Counter Claims
11. Mary Hall, CEO of iHealthSpot, Inc., is Awarded Membership Into Fort Lauderdale City Limits "Profiles of Excellence"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: